Literature DB >> 9183304

Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults.

Q H Meng1, P Pajukanta, L Valsta, A Aro, P Pietinen, M J Tikkanen.   

Abstract

OBJECTIVES: To analyse the association between the G/A polymorphism in the apolipoprotein A-1 (apo A-1) promoter region and plasma lipid levels, as well as their responses to dietary change, in Finnish adults. SUBJECTS AND
DESIGN: Blood samples from 86 subjects (42 men. 44 women) who attended a dietary intervention study carried out in North Karelia in 1993 were available for the current analysis. The diet study consisted of a 2-week baseline period, followed by an 8-week intervention period, and an 8-week switchback period. INTERVENTION: Diet was modified to a low-fat, low-cholesterol diet during the dietary intervention. MAIN OUTCOME MEASURES: Fasting plasma lipid, lipoprotein and apoliprotein levels were determined.
RESULTS: At baseline, the high-density lipoprotein (HDL) cholesterol and apo A-1 levels were higher (P < 0.01) and the triglyceride levels were lower (P < 0.05) in men, but not in women, with the A allele. The differences in HDL cholesterol and apo A-1 levels between genotypes remained during the lowfat, low-cholesterol diet and switchback periods. Apart from the difference between responses in apo A-1 during switchback to the original diet, lipid responses to dietary change did not differ significantly between genotypes.
CONCLUSION: Our findings indicate a significant association between the apo A-1 promoter polymorphism and plasma apo A-1 and HDL-cholesterol in men. In theory, the higher plasma HDL-cholesterol and apo A-1 levels in the GA/AA group may confer some protection against coronary artery disease. The differences in HDL-cholesterol and apo A-1 levels between genotypes persisted during different diets suggesting that the possible benefit is independent of fat and cholesterol intake.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9183304     DOI: 10.1046/j.1365-2796.1997.122139000.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Neonatal examination and screening trial (NEST): a randomised, controlled, switchback trial of alternative policies for low risk infants.

Authors:  C M Glazener; C R Ramsay; M K Campbell; P Booth; P Duffty; D J Lloyd; A McDonald; J A Reid
Journal:  BMJ       Date:  1999-03-06

2.  Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.

Authors:  F Cardona; F J Tinahones; E Collantes; A Escudero; E García-Fuentes; F J Soriguer
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

3.  Synergistic effect between apolipoprotein E and apolipoprotein A1 gene polymorphisms in the risk for coronary artery disease.

Authors:  Taranjit Singh Rai; Madhu Khullar; B S Sehrawat; Monica Ahuja; Praveen Kumar Sharma; Rajesh Vijayvergiya; Anil Grover
Journal:  Mol Cell Biochem       Date:  2008-04-09       Impact factor: 3.396

4.  Treatment of dyslipidemia: genetic interactions with diet and drug therapy.

Authors:  J M Ordovas; E J Schaefer
Journal:  Curr Atheroscler Rep       Date:  1999-07       Impact factor: 5.967

5.  Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease.

Authors:  BiHong Liao; KeQi Cheng; ShaoHong Dong; HuaDong Liu; ZhengLei Xu
Journal:  Diagn Pathol       Date:  2015-07-16       Impact factor: 2.644

6.  ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein(a); anti- vs. pro-Atherogenic properties.

Authors:  Ali I Albahrani; Jannete J Usher; Mohammed Alkindi; Eileen Marks; L Ranganath; Said Al-yahyaee
Journal:  Lipids Health Dis       Date:  2007-08-06       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.